Kringle Pharma: Announcements of individual stocks regarding the decrease in the amount of capital and capital reserve and the disposal of surplus funds.
Kringle Pharma: Analyst report released by Shared Research Co., Ltd.
Kringle Pharma: Announcements of individual stocks: Joint research with Kanazawa University has begun on the application research of HGF (hepatocyte growth factor) for idiopathic pulmonary fibrosis.
Kringle Pharma: Announcements of individual stocks: Update of the financial report for the second quarter of the September 2024 period.
Kringle Pharma: Announcements of individual stocks regarding the establishment of a record date for the convening of an extraordinary general meeting of shareholders.
Kringle Pharma: Presentation at the 2nd Spinal Cord Injury Investor Symposium.
Kringle Pharma: Announcements of individual stocks: Speech at the 2nd Annual Spinal Cord Injury Investor Symposium in the USA.
KRINGLE PHARMA: Notice Concerning Mass Exercise of Stock Acquisition Rights with Exercise Price Amendment Clause
KRINGLE PHARMA: [Delayed] Financial results for the six months ended 2024/3/31 [Japanese GAAP] (unconsolidated)
KRINGLE PHARMA: Notice of publication of a transcript of the financial results briefing for the 2nd quarter of the fiscal year ending 2024/9 Logme Finance
KRINGLE PHARMA: Notice of determination of generic names for HGF pharmaceuticals in Japan
KRINGLE PHARMA: Notice of video posting of financial results briefing for the 2nd quarter of the fiscal year ending September 2024
KRINGLE PHARMA: Addition of clinical trial implementation facilities (Sanno Medical Center) to phase III clinical trials of HGF (hepatocyte growth factor) for vocal cord scars
KRINGLE PHARMA: A review article on the development of HGF therapeutics for central nervous system diseases such as ALS was published in the journal “Pharmacia”
KRINGLE PHARMA: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause
KRINGLE PHARMA: Joint research with Gifu University on applied research on HGF (hepatocyte growth factor) to idiopathic femoral head necrosis
KRINGLE PHARMA: Notice regarding the 2023 grant amount decision for rare disease drug testing research grants for development costs of recombinant human HGF proteins targeting acute spinal cord injury
KRINGLE PHARMA: (Correction) Partial correction to “Notice of holding financial results briefings and live streaming (Zoom webinar)”
KRINGLE PHARMA: Announcement of financial results briefings and live streaming (Zoom webinars)
KRINGLE PHARMA: Notice of provision of collateral in connection with the AMED CiCle business agreement
No Data